The Windsor Framework – what does it mean for life sciences?
For more than two years Northern Ireland has faced difficulties trading with the wider UK. The 2020 Northern Ireland Protocol established systems for trade in and out of Northern Ireland, but has led to a mass of practical difficulties both in the flow of goods across the Irish Sea, and legal compliance for businesses operating […]
For more than two years Northern Ireland has faced difficulties trading with the wider UK. The 2020 Northern Ireland Protocol established systems for trade in and out of Northern Ireland, but has led to a mass of practical difficulties both in the flow of goods across the Irish Sea, and legal compliance for businesses operating in the province. The new Windsor Framework will not please everyone. However, it offers solutions that, if implemented, promise to address many of these problems.
Points to note for the life sciences sector include:
- There will be a move away from the application of EU rules and authorisation requirements for medicines, so that UK law will apply in Northern Ireland and the UK regulator, the MHRA, will be responsible for approval of medicines for the Northern Ireland market.
- The Falsified Medicines Directive will not apply in Northern Ireland.
- Northern Ireland business will still have access to the EU single market where their goods are compliant with EU law.
- Veterinary medicines remain to be addressed, although a grace period for goods from GB to flow into NI lasting until the end of 2025 is planned while a long-term solution is found.
Medical devices do not receive specific attention in the deal, suggesting that there will be no change to the current requirement to follow EU law in the Northern Ireland market. This is disappointing – the existing system is complex and difficult for suppliers to navigate. If the Windsor Framework goes well, however, there might be room for the addition of other product classes like medical devices to its scope.
Finally, unblocking of the Northern Ireland Protocol is expected to lead to progress in other areas. Important here is association to the Horizon Europe programme on scientific collaboration. Stalemate on this issue has been a source of frustration for UK researchers for a long time, and stop gap proposals, although welcome, are considered to fall short of what is needed for innovation to flourish. Hopes are now rising that a breakthrough will soon follow.
Warning: Undefined array key "author_person" in /home/b4business/public_html/wp-content/themes/b4-2020/functions.php on line 121
Warning: Trying to access array offset on value of type null in /home/b4business/public_html/wp-content/themes/b4-2020/functions.php on line 121
More in Science
Stephen Clarke: Leading the Way at the ATOM Festival of Science...
Stephen Clarke, our Principal at Cherwell College Oxford, is not only a distinguished leader and former British diplomat, but also a passionate advocate for science and education. As the Chairman of ATOM Festival of Science & Technology, Stephen plays a pivotal role in bringing world-class scientific discussions and innovations to the heart of Abingdon. Stephen’s leadership ensures that the festival remains dynamic, inclusive, and engaging for people of all ages.
Intertronics: Driving Innovation in Adhesives and Assembly Solutions
For over four decades, Intertronics has been at the forefront of providing high-performance adhesives, coatings, sealants, and application equipment to industries that demand precision and reliability. From electronics and medical devices to automotive and aerospace, Intertronics’ expertise ensures that manufacturers can optimise their bonding and assembly processes with cutting-edge solutions.
Owen Mumford: 70 Years of Innovation in Healthcare
Owen Mumford has been at the forefront of medical device innovation for over 70 years, pioneering solutions that enhance patient care and improve healthcare outcomes worldwide. Established in 1952 by Ivan Owen and John Mumford, the company has grown into a global leader in medical device design and manufacturing, with a commitment to quality, sustainability, and patient-centred innovation.
From this author
End of 2025: Business reflections from Mills & Reeve
As we wrap up 2025, it’s a good moment to pause and reflect on what’s been an eventful year for Oxfordshire and to look ahead at what’s on the horizon for 2026.
Innovation gap opening due to varying AI adoption – Mills &...
An innovation and governance gap is opening up between businesses that realise the potential of GenAI and those that see its impact as limited, our new report has found.
According to The Critical AI Window, organisations that don’t find ways to capitalise on the potential of AI to drive innovation and growth run the risk of being left behind. As a result, competitive edge is at risk.
Our report shows that less than a third of businesses (31%) are using GenAI, with only one-fifth (22%) seeing it as high value.
Paul Knight, partner at Mills & Reeve said: “There is a clear divide amongst businesses – between those that have bought into AI and are building systems and processes around it, and those that are still unsure of its impact beyond mid- to low-value tasks, such as reducing administration and improving efficiencies and productivity.
“This divide is opening up an innovation and governance gap, as early innovators seize on the opportunities that AI presents. While our research shows that the number of businesses using GenAI is likely to rise to 72% by 2027, the lag in performance between then and now could become insurmountable.”
The report highlights the biggest concerns felt by businesses over AI adoption. The majority (90%) are concerned about inaccuracy, more than eight in ten are worried about safety risks (85%), such as cyber attacks, with the impact on future employment also a cause for concern. However, despite 83% of respondents stating that are worried about regulatory compliance, only 31% of businesses have a risk mitigation strategy in place.
Paul added: “The explosion of GenAI has seen a raft of regulations introduced across the world, with more likely, and all of them subject to change as AI understanding develops. In the UK, the regulation of AI relies on existing legal frameworks such as intellectual property, data protection and contract law, highlighting the growing need for these frameworks to be adapted to address the novel risks and complexities introduced by AI technologies. All this suggests that there will be no steady state for regulation for some time.”
However, the risk of not complying is significant, both reputationally and financially. Within the EU, under the EU AI Act, for example, violations can cause administrative fines of €35 million or 7% of total global turnover, whichever is greater.
“There is a real need for businesses to set their own guardrails as legislation in the UK catches up. If they don’t fully understand the legal and ethical boundaries – whether around data protection, intellectual property, or equality law – the consequences could be profound. A single misjudgement could expose the organisation to group litigation.”
Mills & Reeve announces record turnover of £181m as new head...
Leading UK law firm Mills & Reeve has announced turnover growth of £13 million over the 2024/25 financial year, resulting in a new high annual turnover of £181 million. Its Oxford office has seen standout success, with 55% fee growth and a new head of office appointed to lead its next chapter.